On Wednesday,
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: BTHCF, Forum) reported that it had received positive feedback from Health Canada on its plan to conduct a phase 2 COVID-19 clinical study in Canada, with its repurposed drug NP-120 (Ifenprodil).
For more on this news,
click here.
The clinical stage pharmaceutical development Company recently finalized the protocol for its planned physician initiated Phase 2 clinical study of
Ifenprodil for COVID-19 coronavirus-infected patients in South Korea.
FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.